Taegwon Oh has been engaged in drug research and development for more than 25 years, starting with his graduate studies at Seoul National University College of Pharmacy, where he participated in antibiotic drug research. He conducted drug discovery and evaluation research for anti-TB drugs at the NIH with support from the Bill & Melinda Gates Foundation, and oversaw clinical trials and translational research for anti-TB drugs as deputy director at the International Tuberculosis Institute. He joined Cellid as head of R&D, and successfully lead the Korea's first gene-modified cell therapeutic from discovery to phase 2 trial for cancer patients. He served as a senior advisor at Korea Drug Developmet Fund, then joined ILAb as a CEO.